Herpes Zoster

New England Journal of Medicine

Volumn 369, Issue 3, 2013, Pages 255-263

  Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; FAMCICLOVIR; FOSCARNET; FOSCARNET SODIUM; GABAPENTIN; GLUCOCORTICOID; LIDOCAINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OXYCODONE; PARACETAMOL; PLACEBO; PREDNISONE; PREGABALIN; TRAMADOL; VALACICLOVIR; VARICELLA ZOSTER VACCINE; VIRUS DNA; ANALGESIC AGENT; ANTIVIRUS AGENT;

ANEMIA; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; ATAXIA; BEDTIME DOSAGE; BELL PALSY; BLURRED VISION; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DNA DETERMINATION; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GRANULOCYTOPENIA; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOCOMPROMISED PATIENT; IMMUNOFLUORESCENCE TEST; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; KIDNEY FAILURE; MALAISE; MOOD CHANGE; NAUSEA; PAIN; PERIPHERAL EDEMA; POLYMERASE CHAIN REACTION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; URINE RETENTION; VACCINATION; VASCULAR DISEASE; VOMITING; WEIGHT GAIN; XEROSTOMIA; AGED; MALE; REVIEW;

AGED; ANALGESICS; ANTIVIRAL AGENTS; GLUCOCORTICOIDS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; NEURALGIA, POSTHERPETIC; PAIN;

MLCS; MLOWN;

EID: 84880407617     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1302674     Document Type: Article

References (42)

1. Rimland D, Moanna A. Increasing incidence of herpes zoster among veterans. Clin Infect Dis 2010;50:1000-5.
2. Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 1987;7:174-8. (Pubitemid 17049976)
3. Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK. Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol 2008;144:603-8. (Pubitemid 351724420)
4. Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol 2009;8:731-40.
5. de Jong MD, Weel JF, van Oers MH, Boom R, Wertheim-van Dillen PM. Molecular diagnosis of visceral herpes zoster. Lancet 2001;357:2101-2. (Pubitemid 32607456)
6. Sauerbrei A, Eichhorn U, Schacke M, Wutzler PJ. Laboratory diagnosis of herpes zoster. J Clin Virol 1999;14:31-6. (Pubitemid 29454635)
7. Mehta SK, Tyring SK, Gilden DH, et al. Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis 2008;197:654-7. (Pubitemid 351364462)
8. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44:Suppl 1:S1-S26. (Pubitemid 44956795)
9. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.
10. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed) 1986;293:1529-32. (Pubitemid 17016349)
11. Huff JC, Bean B, Balfour HH Jr, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988;85:84-9.
12. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896-900. (Pubitemid 24094969)
13. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia - a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:89-96.
14. Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994;4:241-6. (Pubitemid 24334158)
15. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53.
16. Lin WR, Lin HH, Lee SS, et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect 2001;34:138-42. (Pubitemid 32641346)
17. Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 2003;59:49-56. (Pubitemid 36773890)
18. Balfour HH Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983;308:1448-53. (Pubitemid 13103445)
19. Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients: a randomized comparison of acyclovir and vidarabine. N Engl J Med 1986;314:208-12. (Pubitemid 16183151)
20. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009;2:CD006866.
21. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000;9:863-9.
22. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996;125:376-83. (Pubitemid 126449707)
23. Dworkin RH, Barbano RL, Tyring SK, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009;142:209-17.
24. Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005;65:444-7. (Pubitemid 41099809)
25. Lin PL, Fan SZ, Huang CH, et al. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg Anesth Pain Med 2008;33:320-5.
26. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8. (Pubitemid 29182702)
27. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215-24. (Pubitemid 33016615)
28. Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain 2008;9:1006-17.
29. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41. (Pubitemid 28283261)
30. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59:1015-21.
31. Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011;12:99-109.
32. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374:1252-61.
33. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34. (Pubitemid 40411499)
34. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
35. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54:922-8.
36. Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008;197:Suppl 2:S228-S236. (Pubitemid 351590176)
37. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012;55:1320-8.
38. Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis 2013 May 31 (Epub ahead of print).
39. Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012;206:190-6.
40. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009;200:1068-77.
41. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007;35:Suppl 2:S65-S164. (Pubitemid 350213178)
42. Lopez AS, Burnett-Hartman A, Nambiar R, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis 2008;197:646-53. (Pubitemid 351364461)